Cross-Validation of Insurer and Hospital Price Transparency Data
Real-world cross-validation of insurer and hospital price transparency data finds low overlap but high concordance between data sources.
Facts About Hospital-Insurer Contracting
This study leverages newly available hospital pricing data to explore hospital-insurer contracts from a large hospital chain.
The Price Paradox of Biosimilar-Like Long-Acting Insulin
Findings suggest that Basaglar was not less expensive for patients than Lantus. Empirical evaluation of biosimilar costs prior to automatic substitution is necessary.
